South African healthcare professionals are urging caution in the wake of a recent study that links a rare but potentially life-threatening brain disorder to certain diabetes medications, including popular brands Ozempic and Wegovy.
The study, published in the international medical journal ‘The Hill’, found that a small number of people taking these GLP-1 (glucagon-like peptide-1) receptor agonists developed a vitamin deficiency that triggered a rare brain disorder. While the incidence rate is relatively low, the implications can be serious.
What is GLP-1 and How Does it Affect the Brain?
GLP-1 is a hormone that helps regulate blood sugar levels. Medications like Ozempic and Wegovy mimic the effects of this hormone, helping to lower blood sugar levels and often assisting in weight loss. These drugs are widely used in the treatment of type 2 diabetes, a condition prevalent in South Africa.
However, the study revealed that these medications can, in rare cases, lead to a deficiency in vitamin B1 (thiamine). This deficiency can, in turn, trigger a condition known as Wernicke’s encephalopathy, a serious brain disorder that can cause mental confusion, uncontrolled muscle movement, and even coma or death in severe cases.
The South African Context
These findings are particularly relevant to South Africa, where diabetes is the second biggest cause of death according to the South African Medical Research Council. With an estimated 3.5 million South Africans living with diabetes, the use of GLP-1 receptor agonists is widespread.
Doctors and pharmacists are being urged to monitor patients on these medications closely for signs of vitamin B1 deficiency. Symptoms can include fatigue, confusion, and difficulty walking.
While the study’s findings are concerning, it is important to note that the incidence of Wernicke’s encephalopathy in patients taking GLP-1 receptor agonists is still extremely rare. Patients are advised not to stop taking their medication without first consulting their healthcare provider.
Stay informed and stay safe. Consult with your healthcare provider for any health concerns.
Source: “GLP-1-driven vitamin deficiency linked to rare brain disorder: Study” – The Hill
